Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Organizing cancer genetics programs: the Swiss model.

G Pichert1, R A Stahel

  • 1Division of Oncology, Department of Medicine, University Hospital, Zürich, Switzerland.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.

ESMO open·2022
Same author

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

The Swiss Institute for Applied Cancer Research (SIAK) Network established standards for cancer predisposition testing and counseling. This coordinated effort ensures advanced genetic services and knowledge for improved cancer risk assessment and prevention strategies.

Area of Science:

  • Oncology
  • Genetics
  • Public Health

Background:

  • Inherited cancer predisposition requires multidisciplinary approaches for risk assessment, counseling, and management.
  • An integrated infrastructure is essential for delivering clinical services and conducting research in cancer genetics.

Purpose of the Study:

  • To establish a network for cancer predisposition testing and counseling in Switzerland.
  • To standardize clinical services, coordinate research, and address psychosocial/ethical issues in genetic counseling.
  • To translate acquired knowledge into practical medical applications for inherited cancer risk.

Main Methods:

  • The Swiss Institute for Applied Cancer Research (SIAK) Network for Cancer Predisposition Testing and Counseling was founded in 1999.
  • Development of a consensual algorithm for genetic testing and counseling across eight regional centers.

Related Experiment Videos

  • Proposal for a Swiss databank to characterize BRCA1/BRCA2 mutation patterns and identify unique mutations.

    • Main Results:

    • An established algorithm is currently utilized by eight regional SIAK Network centers for genetic testing and counseling.
    • A proposal for a national databank on BRCA1 and BRCA2 mutations has been submitted.
    • Standardized protocols facilitate consistent genetic evaluation for families with inherited cancer risk.

    Conclusions:

    • The SIAK Network ensures state-of-the-art genetic testing and counseling services in Switzerland.
    • The coordinated effort enhances knowledge acquisition for effective risk assessment and prevention strategies.
    • This initiative improves management of individuals with inherited cancer predisposition.